Prescribing information

 

Key efficacy, quality of life and safety data for Xolair in SAA.

Think sustained exacerbation reduction

Xolair can result in a 70% reduction in exacerbations, even at 4 years.1

 

Efficacy

 

Preview of dosing and self-administration resources
Preview of mode of action video
Preview of Professor Stephen Holgate video

 

 

Xolair can result in a 70% reduction in exacerbations, even at 4 years†1

(Real-world data. In the INNOVATE RCT, 83.2% of patients were free from severe exacerbations over 28 weeks vs 73.8% of placebo patients [n=419, p=0.002]. In the same trial, a 26% reduction in clinically significant asthma exacerbations was achieved with Xolair vs placebo during the 28-week treatment phase p=0.042; ARR = 0.23 events per treatment period)2

 

 

 

Xolair has a response rate of up to 82.4%§3

 

Works regardless of eosinophil levels4

 

 

Timeline showing exacerbation reduction data with Xolair at 16 weeks, 28 weeks, 52 weeks and 4 years

of patients were free from severe exacerbations

Results over 16 weeks of treatment in a real-world study (n=132)5

of patients were free from severe exacerbations over 28 weeks

vs 73.8% of placebo patients (n=419, p=0.002)2

reduction in the rate of asthma exacerbations during the 12 months post Xolair initiation

Reduction in the rate of asthma exacerbations (ARR=1.0 events/year, n=258)3

reduction in severe asthma exacerbations

Reduction from 2.27 at baseline to 0.66 at 4 years (n=60, p<0.0001)1

In INNOVATE, the primary endpoint was the rate of clinically significant asthma exacerbations** during the 28-week double-blind treatment phase. The primary endpoint was met in the PITT population after adjustment for baseline exacerbation history (0.68 with Xolair and 0.91 with placebo; rate ratio 0.738 [95% CI: 0.552–0.998]; p=0.042). In the primary analysis not accounting for previous exacerbations, the treatment group difference was of a similar magnitude but failed to reached statistical significance (rate ratio 0.806; p=0.153).2

 

Think rapid response rates in your patients

Xolair showed response rates of up to 82.4% as early as week 16 in a real-world study.5

 

 

Preview of Professor Stephen Holgate video

 

Preview of patient assessment pad
 

 

Preview of patient assessment pad

 

Preview of Your Questions Answered
 
 

Think effectiveness regardless of patient eosinophil levels

Xolair is effective in IgE-mediated asthma regardless of eosinophil levels.4
 

The retrospective STELLAIR study demonstrates Xolair’s effectiveness for severe persistent allergic asthma regardless of blood eosinophil count, which exceeded 300 cells/μl in a large proportion of patients.4

 

Adapted from Humbert M et al. 2018.4

 

Think oral corticosteroid reduction

In a real-world study, Xolair reduced the burden of OCS on patients. Within a year of Xolair initiation, patients requiring continuous OCS treatment were able to3:

  • Stop OCS use completely (15.8% of patients)
  • Reduce their OCS use by 20% (42.1% of patients)

A 4-year, non-interventional, retrospective, observational, multicentre study in 60 patients (aged ≥12 years) with poorly controlled severe persistent allergic asthma despite treatment with a high-dose ICS and a LABA according to the GINA guidelines.1

Endpoints1:

Effectiveness of Xolair, at 4 months, 1 year and 4 years, as add-on therapy in relation to:

•    Lung function (FEV1 and FVC)

•    Number of severe exacerbations (patient required a systemic corticosteroid, required an emergency room visit, or was hospitalised for the exacerbation)

•    Level of asthma control

•    Daily dose of ICS

A prospective, open-label, observational, multicentre 52-week study in 158 patients (aged ≥12 years) with severe persistent allergic asthma despite treatment with an ICS and a LABA5.

Primary objectives5:

  • Describe the patients who, in the treating physician’s best clinical judgement, were being treated with Xolair
  • Determine the 16- and 52-week effectiveness of Xolair as an add-on therapy by measuring the proportion of patients:
    • improving in 2005 GINA classification
    • with good/excellent GETE rating
    • achieving ≥0.5 point improvement in total AQLQ score
    • severe exacerbation-free (severe exacerbation defined as exacerbation during which the patient required a systemic corticosteroid, or emergency room visit or hospitalisation for the exacerbation     
    • improving in EQ-5D utility (52 weeks only)
  • Describe the treatment patterns involving add-on Xolair treatment
  • Describe the safety and tolerability of treatment with Xolair when used in a pragmatic trial

A randomised, multicentre, placebo-controlled, double-blind, parallel-group study in 419 patients (aged 12–75 years) with severe persistent allergic asthma who were inadequately controlled despite treatment with a high-dose ICS plus LABA, and additional controller medication if required2.

Primary endpoint2:

  • Rate of clinically significant asthma exacerbations (defined as a worsening of asthma symptoms requiring treatment with systemic corticosteroids) during the 28-week double-blind treatment phase

Secondary endpoints included2:

  • Severe exacerbation rate (severe exacerbation defined as PEF or FEV1 <60% of personal best, requiring treatment with systemic corticosteroids)
  • Rate of hospitalisation, emergency room visits, and unscheduled doctor’s visits for exacerbations
  • Symptoms, morning PEF, rescue medication use and FEV1
  • Quality of life at weeks 0, 12 and 28 of the treatment phase (assessed using AQLQ)
  • Treatment effectiveness at treatment end

A multicentre, mixed methodology study assessing the real-life effectiveness of Xolair in 258 patients (aged ≥16 years) with severe persistent allergic asthma3.

Primary endpoint3:

  • Change in mean daily dose of OCS prescribed per patient between the 12-month pre-Xolair and post-Xolair initiation periods

Secondary endpoints included3:

  • Proportion of patients stopping and/or reducing OCS by ≥20%
  • Exacerbation rate (exacerbations requiring either hospitalisation or increase in OCS dose ≥10 mg at any point for at least 3 days)
  • Hospital resource use
  • Lung function
  • Patient-reported outcomes

 

*Xolair provides clinically meaningful improvements in quality of life for patients with severe allergic asthma.6
Data from a non-interventional, observational study of 60 patients with severe persistent asthma receiving treatment with Xolair.
Severe exacerbations were defined as: PEF or FEV1 <60% of personal best, requiring treatment with systemic corticosteroid.
§Data from APEX II, a non-interventional, mixed methodology study of 258 patients aged 16 years with severe persistent allergic asthma, combining retrospective and prospective data collection for 12 months pre- and post-Xolair initiation, respectively.
Severe exacerbations were defined as: exacerbations during which the patient required a systemic corticosteroid, or an emergency room visit or hospitalisation for the exacerbation.
**Clinically significant exacerbations were defined as a worsening of asthma symptoms requiring treatment with systemic corticosteroids.

Indication7: Xolair should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma. In adults and adolescents (12 years of age and older): Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 <80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. In children (6 to <12 years of age): Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.

A&E, accident and emergency; AQLQ, Asthma Quality of Life Questionnaire; ARR, absolute rate reduction; EQ-5D, European quality of life questionnaire 5 dimensions; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GETE, physician-rated global evaluation of treatment effectiveness; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; IgE, immunoglobulin E; ITT, intent-to-treat; LABA, long-acting beta2-agonist; OCS, oral corticosteroids; PEF, peak expiratory flow; PITT, primary intent-to-treat; QoL, quality of life; RCT, randomised controlled trial; SAA, severe allergic asthma.

References

  1. Tzortzaki E et al. Pulm Pharmacol Ther 2012;25(1):77–82.
  2. Humbert M et al. Allergy 2005;60(3):309–316.
  3. Niven RM et al. BMJ Open 2016;6:e011857.
  4. Humbert M et al. Eur Respir J 2018;51(5):1702523.
  5. Brusselle G et al. Respir Med 2009;103(11):1633–1642.
  6. Braunstahl GJ et al. Resp Med 2013;107(8):1141–1151.
  7. Xolair® (omalizumab) Summary of Product Characteristics.
XSA20-C014 July 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]